Adaptive immune system response to measles, mumps, rubella, and hepatitis A viral antigens

The adaptive immune system response to measles, mumps, rubella, and hepatitis A viral antigens represents a coordinated physiological process involving both humoral and cellular immunity. Upon exposure to these antigens—typically via vaccination with live-attenuated (MMR) or inactivated (HepA) viruses—antigen-presenting cells process and present viral epitopes to T-cell receptors (TCR) and B-cell receptors (BCR) [3, 4]. This interaction triggers the clonal expansion of B-lymphocytes, which differentiate into plasma cells secreting neutralizing antibodies (IgG), and the activation of CD4+ and CD8+ T-lymphocytes [1, 2]. The primary goal of this response is the establishment of long-term immunological memory, which allows the host to rapidly recognize and neutralize the respective viruses during future exposures, thereby preventing clinical disease [3]. While this system is the functional endpoint for several major vaccines, it is a multi-component biological pathway rather than a single druggable molecular target [4]. Citations: [1] CDC, Measles, Mumps, and Rubella (MMR) Vaccination (2021); [2] CDC, Hepatitis A Vaccination (2021); [3] StatPearls, Physiology, Immune Response (2023); [4] NIAID, Vaccine Types (2023).

Other names

MMR-HAV immune responseAdaptive immunity to MMRAdaptive immunity to Hepatitis AVaccine-induced immunity to MMR and HAV

Induction of active immunity through the presentation of viral antigens to B and T lymphocytes, leading to the production of neutralizing antibodies and the establishment of immunological memory.